Gelareh Eslamian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gelareh Eslamian has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Bihani Kularatne
Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication- Caroline Wilson
Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK
1 shared publication - Catherine Harper-Wynne
Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK
1 shared publication - Daisy Henderson
Department of Palliative Care, Royal Free London NHS Foundation Trust, London, UK
1 shared publication - Daniel Stephen Poon
Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK
1 shared publication - Debra H. Josephs
Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK
1 shared publication
Latest Publications
- 22 October 2020
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 59 (2) , 29-31
Republished: Immune checkpoint inhibitor induced large vessel vasculitis
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
- 22 October 2020
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 59 (2) , 29-31
Republished: Immune checkpoint inhibitor induced large vessel vasculitis
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
- 1 August 2020
- Published by Elsevier in Clinical Oncology
- Vol. 32 (8) , e169
The Assessment of Bone Mineral Density (BMD) and Fracture Risk after 3 Years of Adjuvant Zoledronic Acid in Postmenopausal (ER+) Early Breast Cancer
- 1 August 2020
- Published by Elsevier in Clinical Oncology
- Vol. 32 (8) , e169
The Assessment of Bone Mineral Density (BMD) and Fracture Risk after 3 Years of Adjuvant Zoledronic Acid in Postmenopausal (ER+) Early Breast Cancer
- Open Access
- 1 February 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 773-779
Efficacy of eribulin in breast cancer: a short report on the emerging new data
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.
- 1 February 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 773-779
Open AccessEfficacy of eribulin in breast cancer: a short report on the emerging new data
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.